BIOMAT Database Logo BIOMAT Database Logo

[Evaluation of phase II drug metabolizing enzymes in the discovery stage]. 2009

Tsuyoshi Yokoi
tyokoi@kenroku.kanazawa-u.ac.jp

UI MeSH Term Description Entries
D004347 Drug Interactions The action of a drug that may affect the activity, metabolism, or toxicity of another drug. Drug Interaction,Interaction, Drug,Interactions, Drug
D004353 Drug Evaluation, Preclinical Preclinical testing of drugs in experimental animals or in vitro for their biological and toxic effects and potential clinical applications. Drug Screening,Evaluation Studies, Drug, Pre-Clinical,Drug Evaluation Studies, Preclinical,Drug Evaluations, Preclinical,Evaluation Studies, Drug, Preclinical,Evaluation, Preclinical Drug,Evaluations, Preclinical Drug,Medicinal Plants Testing, Preclinical,Preclinical Drug Evaluation,Preclinical Drug Evaluations,Drug Screenings,Screening, Drug,Screenings, Drug
D013045 Species Specificity The restriction of a characteristic behavior, anatomical structure or physical system, such as immune response; metabolic response, or gene or gene variant to the members of one species. It refers to that property which differentiates one species from another but it is also used for phylogenetic levels higher or lower than the species. Species Specificities,Specificities, Species,Specificity, Species
D014453 Glucuronosyltransferase A family of enzymes accepting a wide range of substrates, including phenols, alcohols, amines, and fatty acids. They function as drug-metabolizing enzymes that catalyze the conjugation of UDPglucuronic acid to a variety of endogenous and exogenous compounds. EC 2.4.1.17. Glucuronyltransferase,UDP Glucuronosyltransferase,17 beta-Hydroxysteroid UDP-Glucuronosyltransferase,4-Nitrophenol-UDP-Glucuronosyltransferase,7-Hydroxycoumarin UDP Glucuronyltransferase,Androsterone UDP-Glucuronosyltransferase,Bilirubin UDP-Glucuronyltransferase,Estrogen UDP-Glucuronosyltransferase,Estrone Glucuronyltransferase,Glucuronic Transferase,Morphine Glucuronyltransferase,UDP Glucuronyl Transferase,UDP-Glucuronic Acid 3-O-beta-D-Galactosyl-D-Galactose Glucuronosyltransferase,p-Nitrophenyl UDP-Glucuronosyltransferase,17 beta Hydroxysteroid UDP Glucuronosyltransferase,4 Nitrophenol UDP Glucuronosyltransferase,7 Hydroxycoumarin UDP Glucuronyltransferase,Androsterone UDP Glucuronosyltransferase,Bilirubin UDP Glucuronyltransferase,Estrogen UDP Glucuronosyltransferase,Glucuronosyltransferase, UDP,Glucuronyl Transferase, UDP,Glucuronyltransferase, 7-Hydroxycoumarin UDP,Glucuronyltransferase, Estrone,Glucuronyltransferase, Morphine,Transferase, Glucuronic,Transferase, UDP Glucuronyl,UDP Glucuronic Acid 3 O beta D Galactosyl D Galactose Glucuronosyltransferase,UDP Glucuronyltransferase, 7-Hydroxycoumarin,UDP-Glucuronosyltransferase, 17 beta-Hydroxysteroid,UDP-Glucuronosyltransferase, Androsterone,UDP-Glucuronosyltransferase, Estrogen,UDP-Glucuronosyltransferase, p-Nitrophenyl,UDP-Glucuronyltransferase, Bilirubin,p Nitrophenyl UDP Glucuronosyltransferase

Related Publications

Tsuyoshi Yokoi
Phase II drug metabolizing enzymes.
June 2010, Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia,
Tsuyoshi Yokoi
Cancer and phase II drug-metabolizing enzymes.
February 2003, Current drug metabolism,
Tsuyoshi Yokoi
Role of phase II drug metabolizing enzymes in cancer chemoprevention.
July 2009, Current drug metabolism,
Tsuyoshi Yokoi
Functional genetic polymorphisms from phase-II drug metabolizing enzymes.
August 2012, CNS neuroscience & therapeutics,
Tsuyoshi Yokoi
The ontogeny of human drug-metabolizing enzymes: phase II conjugation enzymes and regulatory mechanisms.
February 2002, The Journal of pharmacology and experimental therapeutics,
Tsuyoshi Yokoi
[Human drug metabolizing enzymes. II. Conjugation enzymes].
September 1998, Acta pharmaceutica Hungarica,
Tsuyoshi Yokoi
Pharmacogenomics of phase II metabolizing enzymes and drug transporters: clinical implications.
April 2013, The pharmacogenomics journal,
Tsuyoshi Yokoi
Zerumbone, a tropical ginger sesquiterpene, activates phase II drug metabolizing enzymes.
August 2004, FEBS letters,
Tsuyoshi Yokoi
Molecular mechanism of phase I and phase II drug-metabolizing enzymes: implications for detoxification.
January 2007, International review of cytology,
Tsuyoshi Yokoi
The expression of Phase II drug-metabolizing enzymes in human B-lymphoblastoid TK6 cells.
January 2022, Journal of environmental science and health. Part C, Toxicology and carcinogenesis,
Copied contents to your clipboard!